Research shows that blocking BDNF significantly slows tumor growth in triple-negative breast cancer — Evidence Review
Published in Cell Death & Differentiation, by researchers from University of Oklahoma
Researched by
— the AI search engine for science
Table of Contents
Triple-negative breast cancer may promote its own growth and resistance to treatment by recruiting nerves through immune cell signaling, according to a recent study from the University of Oklahoma. Related research broadly supports the idea that tumor-nerve interactions contribute to cancer aggressiveness and therapy resistance.
- Several studies confirm that nerves infiltrating tumors can promote cancer growth, metastasis, and resistance to treatment, highlighting similar mechanisms across different cancer types and supporting the new findings 1 2 3 4 6.
- Research into neurotrophic factors—including BDNF and nerve growth factor—demonstrates their roles in facilitating tumor survival, angiogenesis, and invasiveness, in line with the mechanism described in the new study 2 4 6.
- Blocking nerve-cancer signaling pathways, such as those involving BDNF or neuropeptides, has shown therapeutic promise in preclinical models, consistent with the potential treatment strategies indicated by the current research 1 6.
Study Overview and Key Findings
Recent advances in the understanding of tumor microenvironments have highlighted the role of nerves in cancer progression, but the origins and implications of tumor innervation in breast cancer remain incompletely understood. This study addresses a critical gap by identifying how triple-negative breast tumors manipulate immune cells to attract nerves, which in turn may help the cancer grow and resist therapy. The findings are particularly significant given the aggressive nature and limited treatment options for triple-negative breast cancer.
| Property | Value |
|---|---|
| Study Year | 2026 |
| Organization | University of Oklahoma |
| Journal Name | Cell Death & Differentiation |
| Authors | Jumana Abbadi, Rameswari Velayutham, Anand C. Annan, Amin Reza Nikpoor, Maryam Ahmadi, Beatriz G. S. Rocha, Jacob W. Farriester, Jessica M. Reel, Eric C. Holland, Frank Szulzewsky, Alexander Birbrair, Kar-Ming Fung, Sebastien Talbot, Maureen A. Cox |
| Population | Patients with triple-negative breast cancer |
| Methods | Animal Study |
| Outcome | Tumor growth, nerve recruitment, immune response |
| Results | Blocking BDNF slowed tumor growth significantly. |
Literature Review: Related Studies
To provide context for the new findings, we searched the Consensus database, which includes over 200 million research papers. The following specific search queries were used to identify relevant studies:
- breast cancer nerve growth mechanisms
- BDNF tumor growth inhibition
- cancer treatment resistance neural pathways
Below, key topics and findings from the literature are summarized:
| Topic | Key Findings |
|---|---|
| How do nerves and neural factors influence breast cancer growth and metastasis? | - Tumor innervation is associated with increased metastasis and poor outcomes in breast cancer 1 3. - Neuronal factors such as substance P and nerve growth factor stimulate tumor growth, invasion, and angiogenesis 1 2 4. |
| What is the role of neurotrophic factors (e.g., BDNF) in cancer progression and resistance? | - BDNF and related neurotrophins support tumor cell survival and can be targeted to inhibit growth in breast and other cancers 6 8 9. - BDNF/TrkB signaling is implicated in therapy resistance and disease progression 8 9. |
| Can targeting neural signaling or nerve-cancer interactions reduce tumor growth or resistance? | - Pharmacological inhibition of neuropeptide or neurotrophin pathways (e.g., TACR1, TrkA, TrkB) suppresses tumor growth and metastasis in experimental models 1 4 6. - Disrupting nerve-tumor crosstalk may enhance immune responses and reduce progression 5. |
| How do tumor microenvironment and non-genetic mechanisms contribute to therapy resistance? | - Non-genetic mechanisms (e.g., microenvironmental cues, cell plasticity, neural signaling) enable tumors to adapt and resist therapies 11 12 13 14 15. - Tumor-nerve interactions are among several microenvironmental factors influencing resistance 13 14. |
How do nerves and neural factors influence breast cancer growth and metastasis?
Multiple studies indicate that increased nerve presence within breast tumors correlates with greater metastatic potential and poorer outcomes. The new study adds mechanistic detail by showing how immune cells can recruit nerves into the tumor microenvironment, aligning with reports of neuronal factors actively promoting tumor progression.
- Tumor innervation is linked to higher rates of breast cancer metastasis and poor patient survival 1 3.
- Neuronal release of substance P and other neuropeptides enhances tumor invasion and metastatic spread 1.
- Nerve growth factor stimulates angiogenesis and supports the invasive behavior of breast cancer cells 2 4.
- The recruitment and activation of nerves may be a common feature in aggressive cancers, reinforcing the findings of the new study 1 2 3.
What is the role of neurotrophic factors (e.g., BDNF) in cancer progression and resistance?
There is broad agreement that neurotrophic factors such as BDNF and NGF play a significant role in cancer cell survival, proliferation, and resistance to treatment. The new study's focus on BDNF as a mediator of nerve recruitment and tumor growth in triple-negative breast cancer is consistent with prior work demonstrating the importance of these pathways.
- BDNF is expressed and secreted by breast cancer cells, contributing to cell survival and resistance to apoptosis 6.
- BDNF/TrkB signaling has been implicated in poor prognosis and drug resistance in several cancer types, including gastric and breast cancers 8 9.
- Blocking BDNF or its receptors in preclinical models leads to reduced tumor growth and increased cell death 6 8 9.
- The new study extends this knowledge by showing that immune-cell-derived BDNF promotes nerve recruitment, which further supports tumor progression.
Can targeting neural signaling or nerve-cancer interactions reduce tumor growth or resistance?
Therapeutic targeting of nerve-cancer crosstalk is an emerging area with growing evidence of efficacy in preclinical settings. The new study's demonstration that BDNF inhibition can slow tumor growth aligns with studies targeting similar neural pathways.
- Inhibitors of neuropeptide and neurotrophin signaling (e.g., TACR1 antagonists, TrkA/TrkB inhibitors) reduce tumor growth, metastasis, and resistance 1 4 6.
- Interventions that disrupt neural circuits between tumors and the brain have shown potential for modulating tumor progression and immune responses 5.
- Targeting nerve-cancer signaling may enhance the effectiveness of existing treatments by overcoming microenvironment-induced resistance 5 6.
- The current study's findings support the concept that disrupting neural inputs to tumors is a viable therapeutic strategy.
How do tumor microenvironment and non-genetic mechanisms contribute to therapy resistance?
Non-genetic adaptation, including the influence of the tumor microenvironment and neural signaling, is increasingly recognized as central to therapeutic resistance in cancer. The recruitment of nerves and the resulting changes in tumor biology represent one such adaptive mechanism.
- Tumors exploit microenvironmental cues—including neural inputs—to adapt and survive under therapeutic pressure 11 12 13 14.
- Cell plasticity and lineage switching, sometimes driven by neural factors, contribute to therapy resistance and disease progression 11 12.
- Nerve-cancer interactions can enhance metabolic adaptability and immune evasion, both key features of resistance 3 13.
- Understanding and targeting these microenvironmental and non-genetic mechanisms are critical for developing more durable treatment responses 13 14 15.
Future Research Questions
Despite progress in understanding the role of nerves and neurotrophic factors in breast cancer, several important questions remain. Further research is needed to clarify how these mechanisms operate in human disease, identify optimal therapeutic targets, and determine the broader applicability of these findings across cancer types.
| Research Question | Relevance |
|---|---|
| How does nerve recruitment by immune cells affect therapy response in human breast cancer? | Understanding this mechanism could inform strategies to overcome resistance and improve patient outcomes, as nerve-tumor interactions are linked to progression and resistance 1 6 13. |
| Can BDNF inhibitors improve survival in patients with triple-negative breast cancer? | Preclinical models suggest BDNF blockade slows tumor growth, but clinical trials are necessary to determine safety and efficacy in human patients 6 8 9. |
| What are the mechanisms by which tumor-infiltrating nerves promote metastasis? | Metastatic spread is a key challenge in breast cancer; elucidating nerve-related mechanisms may reveal new intervention points for limiting dissemination 1 3 4. |
| Does targeting tumor-nerve interaction enhance immunotherapy efficacy? | Nerve-mediated immunosuppression is suggested by several studies; combining nerve-targeted therapies with immunotherapy could improve outcomes 5 13 14. |
| Are similar nerve-immune recruitment mechanisms present in other aggressive cancers? | Understanding whether the mechanism is unique to triple-negative breast cancer or common across cancers could broaden therapeutic applications 2 3 8. |